Individual Variations of Taste and Smell Perception in Alcohol Use Disorder (AUD)
NCT05677321
Recruiting
Background: Alcohol use disorder (AUD) is the most common substance use disorder in the world. Long-term AUD can affect a person s sense of taste and smell. This natural history study will compare alcohol drinking behaviors and measures of taste and smell in people with and without AUD. Objective: To understand how alcohol use changes the senses of taste and smell. Eligibility: People aged 18 to 65 years with or without AUD. Design: Participants will be screened. They will have several te... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Alcohol Use Disorder
Register for Updates
VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study
NCT06249555
Recruiting
The primary aim of this study is to explore the time course of response to Vedolizumab in participants with CD as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference-short form (SF), as well as other PROMIS domain SFs (fatigue, anxiety, depression, sleep disturbance, physical function, and ability to participate in social roles and activities); other PRO measures will also be assessed.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: GI Alliance - Sun City, Sun City, Arizona +19 locations
Conditions: Crohn's Disease
Register for Updates
Investigation of the Effects of a Bifidobacterial Strain on Bowel Movement in Healthy Adults
NCT06686420
Recruiting
The goal of this clinical trial is to investigate whether a supplement containing the B. longum strain works to alleviate constipation in adults. The main questions it aims to answer are: Does a supplement containing the B. longum strain increase the number of spontaneous bowel movements per week, improve stool consistency, and enhance the quality of life? Participants will: Take a supplement containing the B. longum strain or a placebo every day for 8 weeks. Maintain an e-diary as per the... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/31/2025
Locations: Atlantia Clinical Trials, Chicago, Illinois
Conditions: Infrequent Bowel Movements
Register for Updates
Immuno-Oncology Database and Bioregistry
NCT04656873
Recruiting
Immunotherapy, especially immune checkpoint inhibitors (ICIs), are effective in treating many different types of cancers. ICIs fight cancer by driving the immune system into an "activated state" that makes it harder for tumor cells to hide and easier for the immune system to destroy them. In doing this, oncologists risk "over activation" where immune cells can cause side effects that could affect any part of the body. These are known as immune related adverse events (irAEs). While irAEs are a kn... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill, North Carolina
Conditions: Malignancy, Immune System Diseases, Autoimmune Diseases
Register for Updates
Trial for Reliability of Urodynamics SysTem
NCT05694793
Recruiting
The goal of this prospective trial is to assess the safety and reliability of the Glean Urodynamics System (GUS) in adult females with lower urinary tract symptoms. The main question\[s\] it aims to answer are: • What is GUS's ability to safely and reliably conduct wireless, catheter-free monitoring of vesical pressure compared to the vesical pressures collected with conventional urodynamics? Participants will undergo a conventional urodynamics exam, a simultaneous urodynamics exam with GUS, a... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: University of California San Diego, San Diego, California +1 locations
Conditions: Urologic Diseases, Urodynamics
Register for Updates
Study of Circadian Focused Light Therapy in Progressive Multiple Sclerosis
NCT06261528
Recruiting
The study is being done to determine if treatment with a novel form of light therapy is tolerated in patients with progressive multiple sclerosis. The goal of this trial to establish the safety profile of this light therapy while generating data on its impact on fatigue, as well as its mechanism of action. Fatigue is often a complex symptom in multiple sclerosis, without any FDA-approved direct therapy. Fatigue is traditionally treated with symptom management through a multidisciplinary team.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Progressive Multiple Sclerosis
Register for Updates
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
NCT06710847
Recruiting
Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat. The study will test whether GSK4418959 alone or in combination with a PD-1 inhibitor agent can decrease tumor size, is safe, well-tolerated, and how amounts of the study drug decrease in the body over time.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: GSK Investigational Site, Denver, Colorado +3 locations
Conditions: Neoplasms, Colorectal, Solid Tumor, Colon Cancer, Rectal Cancer, Endometrial Cancer
Register for Updates
Video Telehealth Exercise Training in Cystic Fibrosis
NCT04680403
Recruiting
The purpose of this research study is to begin an exercise program for patients with a cystic fibrosis (CF) exacerbation.
Gender:
ALL
Ages:
19 years and above
Trial Updated:
01/31/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Cystic Fibrosis
Register for Updates
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
NCT05755386
Recruiting
This study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis.
Gender:
ALL
Ages:
Between 12 years and 60 years
Trial Updated:
01/31/2025
Locations: Ronald Reagan UCLA Medical Center, Los Angeles, California +64 locations
Conditions: IC-MPGN
Register for Updates
Personalized Transcranial Direct Current Stimulation in Stroke Recovery
NCT06286800
Recruiting
The central objective of this application is to explore the neural substrate of personalized tDCS (ptDCS) and to determine whether the paradigm for each stroke patient can predict the amount of sustained clinical improvement through increased connectivity as measured by a biomarker of plasticity.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/31/2025
Locations: Houston Methodist Hospital, Houston, Texas
Conditions: Stroke
Register for Updates
PS230005 Control-IQ 1.5 Post-Approval Study
NCT06717451
Recruiting
This 522 post-market surveillance study is a single-arm, decentralized prospective observational cohort study designed to collect safety data on Control-IQ technology v1.5 in children with type 1 diabetes ages 2 to \<6 years old. Participants will use Control-IQ technology v1.5 for 12 months in the real-world setting.
Gender:
ALL
Ages:
Between 2 years and 5 years
Trial Updated:
01/31/2025
Locations: Tandem Diabetes Care, San Diego, California
Conditions: Type 1 Diabetes
Register for Updates
Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix
NCT04723095
Recruiting
This study collects information and data on patients with neuroendocrine cervical cancer. Information from this study may be used to better understand the correlation between clinical data, such as patient characteristics, treatment, and disease outcomes, and overall patient outcomes.
Gender:
ALL
Ages:
All
Trial Updated:
01/31/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Cervical Large Cell Neuroendocrine Carcinoma, Cervical Neuroendocrine Carcinoma, Cervical Small Cell Carcinoma, Cervical Undifferentiated Carcinoma, Stage I Cervical Cancer AJCC v8, Stage IA Cervical Cancer AJCC v8, Stage IA1 Cervical Cancer AJCC v8, Stage IA2 Cervical Cancer AJCC v8, Stage IB Cervical Cancer AJCC v8, Stage IB1 Cervical Cancer AJCC v8, Stage IB2 Cervical Cancer AJCC v8, Stage II Cervical Cancer AJCC v8, Stage IIA Cervical Cancer AJCC v8, Stage IIA1 Cervical Cancer AJCC v8, Stage IIA2 Cervical Cancer AJCC v8, Stage IIB Cervical Cancer AJCC v8, Stage III Cervical Cancer AJCC v8, Stage IIIA Cervical Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8
Register for Updates